REGISTER FOR TOUCH BRIEFINGS |
|
|
|
Register for touch briefings
|
|
|
|
|
|
|
|
Touch Briefings welcomes editorial submissions for inclusion within our print reports and website from industry practitioners.
|
|
|
|
|
|
ACTELION PHARMACEUTICALS US INC. - US CARDIOLOGY 2006 |
|
Address:
5000 Shoreline Court
Suite 200
South San Francisco
CA
94080
Tel. 650 624 6900
Fax. 650 952 0991
www.actelion.com
USMedInfo@actelion.com
Technical Article
Actelion Pharmaceuticals is a research leader in diseases involving the endothelium. Its oral dual endothelin receptor antagonist (ERA), Tracleer®, was approved in 2001 for the treatment of pulmonary arterial hypertension in patients with WHO Class III or IV symptoms, to improve exercise ability and decrease the rate of clinical worsening.
This article appears in US Cardiology 2006
|
|
|
Healthcare & Pharmaceutical Suppliers :
|
Associations
|
|
|
|
